COST Action title: “Network for Optimized Astatine labeled Radiopharmaceuticals” (NOAR) CA19114
Management Committee member: Dr Sanja Vranješ-Đurić, Principal research fellow
COST Action chair: Dr Jean-François GESTIN.
Team members: Management Committee substitute dr Drina Janković, dr Marija Mirković, dr Zorana Milanović.
Project budget: 300.000 EUR
Astatine-211 is now considered as one of the most promising radionuclides for Targeted Alpha Therapy. Thus, the main research aim of Network for Optimized Astatine labeled Radiopharmaceuticals (NOAR) COST Action is to successfully demonstrate that TAT with astatine-211 can become the European standard for treatment of certain cancerous pathologies (glioma, melanoma, multiple melanoma, breast, ovarian, prostate cancer, neuroendocrine tumours, leukaemia, Non Hodgkins Lymphoma, bladder carcinoma, etc.). To this en d, efficient exchange of knowledge and efficient networking are needed as available under the COST Action, which brings together all European stakeholders interested in promotion of astatine-211 for medical applications and allow to associate with partners outside Europe (USA, South Africa, Japan). In order to achieve this main aim, the following scientific, technological,reg ulatory and societal challenges must be addressed: Astatine-211 targetry, production and logistics; Astatine-211 speciation for pharmaceutical production; Design of vectors and radiolabelling techniques for astatine-211; Automation in production of astatine-211 and astatine-211 radiopharmaceuticals; Dosimetry of astatine-211 for TAT; Pharmacoeconomics of TAT with astatine-211 and Communicating TAT with astatine-211.